+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Canada Diabetes Care Drugs and Devices Market - Growth, Trends, and Forecast (2019 - 2024)

  • PDF Icon


  • 125 Pages
  • October 2019
  • Region: Canada
  • Mordor Intelligence
  • ID: 4833539
UP TO OFF until Sep 30th 2023
Market Overview
  • The Canada diabetes care devices market is expected to register a CAGR of about 5.9% during the forecast period (2019-2024).
  • Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country.
  • There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.
  • By Segment Type in devices, the monitoring devices occupy the highest market share of 57.9% for the year 2018. The Self-monitoring blood glucose devices occupy the highest market share with test strips being highest in volume.

Scope of the Report

Segmented by Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by sub-segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors))and Devices( Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring)).

Key Market Trends

Sulfonylureas and Metformin combined market holds 70% of share in Canada Oral diabetes drugs segment
  • Metformin holds 27% of the market share in Canada oral diabetes drugs
  • Metformin has proved to be an effective medication for diabetes treatment when the diet is not enough to provide a healthy way of life. Rather than other drugs that stimulate the release of insulin, metformin increases the body's sensitivity to insulin, thus, helping in reducing a patient’s blood sugar level.
  • Asia-Pacific holds the highest market share due to many generic players in Metformin market.
  • Sulfonylureas hold the highest market in Canada oral diabetes drugs market, second-generation Sulfonylureas which have fewer side effects, include Glipizide (Glucotrol), Glyburide (Micronase, Glynase PresTabs, and DiaBeta), and the newest drug, Glimepiride (Amaryl). A single-dose, extended-release form of Glipizide called Glucotrol XL is also available.

Monitoring Devices holds the highest market share in Canada Diabetes Devices Market
  • Self-monitoring Blood Glucose Devices holds 48.7% of the market share in Canada diabetes devices market.
  • The personal-use glucometer is expected to see high sales in the future, owing to the rising awareness and reducing costs associated with the glucometer.
  • Due to favourable healthcare insurance policies, the glucometer segment of the market studied is expected to witness high growth, during the forecast period.
  • In 2018, test strips use in hospitals and clinics hold 76.7% market share, which. The hospital/clinic’s use of test strips is expected to increase at a CAGR of 7.84%, during the forecast period.

Competitive Landscape
  • There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
  • The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may help to enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with FreeStyle Libre portfolio of products.
  • Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Drivers
4.2 Market Restraints
5 Market Segmentation
5.1 By Drug
5.1.1 Oral anti-diabetic drugs Biguanide (Value and Volume 2012-2024) Metformin Alpha - Glucosidase inhibitors (Value and Volume 2012-2024) Alpha - Glucosidase inhibitors Dopamine -D2 receptor agonist (Value and Volume 2012-2024) Bromocriptin( Cycloset) Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024) Invokana (Canagliflozin) Jardiance (Empagliflozin) Farxiga/Forxiga (Dapagliflozin) Suglat (Ipragliflozin) Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Value and Volume 2012-2024) Januvia (Sitagliptin) Onglyza (Saxagliptin) Tradjenta (Linagliptin) Vipidia/Nesina (Alogliptin) Galvus (Vildagliptin) Sulfonylureas (Value and Volume 2012-2024) Sulfonylureas Meglitinide (Value and Volume 2012-2024) Meglitinide
5.1.2 Insulin Basal or Long Acting Insulins Lantus (Insulin Glargine) Levemir (Insulin Detemir) Toujeo (Insulin Glargine) Tresiba (Insulin Degludec) Basaglar (Insulin Glargine) Bolus or Fast Acting Insulins NovoRapid/Novolog (Insulin Aspart) Humalog (Insulin Lispro) Apidra (Insulin Glulisine) FIASP (Insulin Aspart) Traditional Human Insulins Novolin/Actrapid/Insulatard Humilin
5.1.3 Combination Insulins NovoMix (Biphasic Insulin Aspart) Ryzodeg (Insulin Degludec and Insulin Aspart) Xultophy (Insulin Degludec and Liraglutide) Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
5.1.4 Oral Combination Janumet (Sitagliptin and Metformin HCl)
5.1.5 Non-Insulin Injectable drugs GLP1 receptor agonists Victoza (Liraglutide) Byetta (Exenatide) Bydureon (Exenatide) Trulicity (Dulaglutide) Lyxumia (Lixisenatide) Amylin Analogue Symlin (Pramlintide)
5.2 By Devices
5.2.1 By Monitoring Devices, Value Volume (2012-2024) Self-Monitoring Blood Glucose Glucometer Devices Hospital Personal Blood Glucose Test Strips Hospital Personal Lancets Hospital Personal Continuous Glucose Monitoring Sensors Receivers
5.2.2 By Management Devices, Value Volume (2012-2024) Insulin Pump Insulin Pump Device Insulin Pump Reservoir Infusion Set Insulin Syringes Cartridges in Reusable pens Insulin Disposable Pens Jet Injectors
6.1 Type-1 Diabetic Population (2012-2024)
6.2 Type-2 Diabetic Population (2012-2024)
7.1 Novo Nordisk A/S
7.2 Sanofi Aventis
7.3 Eli Lilly
7.4 AstraZeneca
7.5 Boehringer Ingelheim
7.6 Bristol Myers Squibb
7.7 Roche
7.8 Abbott
7.9 Johnson and Johnson (Lifescan)
7.10 Arkray
7.11 Ascensia Diabetes Care
7.12 AgaMatrix Inc.
7.13 Dexcom
7.14 Medtronic
7.15 Becton Dickinson
7.16 Ypsomed Holding AG
7.17 Terumo
7.18 LMC Diabetes and Endocrinology
7.19 Bayshore Health Care
7.20 Express Scripts
7.21 One Drop
7.22 Telus Health

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novo Nordisk A/S
  • Sanofi Aventis
  • Eli Lilly
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Roche
  • Abbott
  • Johnson and Johnson (Lifescan)
  • Arkray
  • Ascensia Diabetes Care
  • AgaMatrix Inc.
  • Dexcom
  • Medtronic
  • Becton Dickinson
  • Ypsomed Holding AG
  • Terumo
  • LMC Diabetes and Endocrinology
  • Bayshore Health Care
  • Express Scripts
  • One Drop
  • Telus Health